Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ian W Flinn, M.D.
SCRI Development Innovations, LLC
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Providence Medical Group
Terre Haute, Indiana, United States
- Rhhp/ Hope Cancer Center
Terre Haute, Indiana, United States
- St. Louis Cancer Care
Chesterfield, Missouri, United States
- Hematology-Oncology Associates of Northern Nj
Morristown, New Jersey, United States
- Oncology Hematology Care Inc.
Cincinnati, Ohio, United States
- Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2008
- Primary completion
- 30 Apr 2015
- Completion
- 30 Nov 2016
- Last update posted
- 31 Jan 2017
- Registered enrollment
- 39
- Registry id
- NCT00633594
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.